Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and delivery of products for its Psilocybin-for-Neuropsychiatric Disorder, PFN(TM) (“PFN”) program. The agreement is focused on developing oral formulations for Tryp’s proprietary psilocybin active pharmaceutical ingredient (“API”), which is being manufactured by Albany Molecular Research, Inc. The announcement noted Alcami’s broad capabilities, technical expertise and ability to collaborate with customers to consistently deliver high-quality results. Tryp is tentatively planning to manufacture an initial batch of cGMP psilocybin API by September 2021, after which Alcami and Tryp will develop the analytical methods and the final formulation of Tryp’s oral psilocybin product. “Our partnership with Alcami signals the further advancement of our proprietary manufacturing of synthetic psilocybin,” said Tryp president and chief science officer Jim Gilligan, PhD, in the release. “We have been impressed with Alcami’s expertise with developing both final formulations as well as the analytical methods that will ensure the consistently excellent quality of our products.”
To view the full press release, visit https://ibn.fm/U16Cv
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with Dr. Jennifer Miller at the University of Florida. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to Tare available in the company’s newsroom at https://ibn.fm/TRYPF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment